Provided by Tiger Trade Technology Pte. Ltd.

Zentalis Pharmaceuticals, LLC

1.42
+0.08005.97%
Post-market: 1.42-0.0009-0.06%19:08 EST
Volume:4.61M
Turnover:6.44M
Market Cap:102.60M
PE:-0.68
High:1.42
Open:1.34
Low:1.33
Close:1.34
52wk High:3.33
52wk Low:1.01
Shares:72.25M
Float Shares:49.98M
Volume Ratio:6.73
T/O Rate:9.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0805
EPS(LYR):-2.3331
ROE:-49.18%
ROA:-24.51%
PB:0.41
PE(LYR):-0.61

Loading ...

Matrix Capital Management Company LP Reports Disposal of Zentalis Pharmaceuticals Common Shares

Reuters
·
Dec 16

Zentalis Pharmaceuticals Inc - Enters Stock Purchase Agreement With Matrix - SEC Filing

THOMSON REUTERS
·
Dec 16

Zentalis Pharmaceuticals Director Karan Takhar Resigns

Reuters
·
Dec 16

Zentalis Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Nov 13

Zentalis price target lowered to $4 from $8 at Morgan Stanley

TIPRANKS
·
Nov 11

Wedbush Remains a Hold on Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
Nov 11

Zentalis Pharmaceuticals (ZNTL) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Nov 11

Zentalis Pharma Q3 EPS $(0.37) Beats $(0.48) Estimate

Benzinga
·
Nov 11

Zentalis Pharmaceuticals Q3 net loss narrows

Reuters
·
Nov 11

Zentalis Pharmaceuticals reports $280.7 million in cash and maintains guidance for DENALI trial topline data by year end 2026

Reuters
·
Nov 11

BRIEF-Zentalis Pharmaceuticals Q3 EPS USD -0.37

Reuters
·
Nov 11

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

THOMSON REUTERS
·
Nov 11

Zentalis Pharmaceuticals Inc expected to post a loss of 53 cents a share - Earnings Preview

Reuters
·
Nov 08

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 04

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

THOMSON REUTERS
·
Oct 14

Zentalis Pharmaceuticals Inc. Reports Initial Beneficial Ownership by Chief Legal Officer James B. Bucher

Reuters
·
Sep 24

BRIEF-Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Sep 03

BRIEF-Zentalis Pharmaceuticals Appoints James B. Bucher, JD, As Chief Legal Officer And Corporate Secretary

Reuters
·
Aug 27

Zentalis Pharmaceuticals Appoints James B. Bucher, Jd, as Chief Legal Officer and Corporate Secretary

THOMSON REUTERS
·
Aug 27

Zentalis Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 07